|
|
|
|
Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd.,
4070 Basel, Switzerland
We examined the ligand-binding site of the
5-hydroxytryptamine6 (5-HT6) receptor using
site-directed mutagenesis. Interactions with residues in two
characteristic positions of transmembrane region V are important for
ligand binding in several bioamine receptors. In the 5-HT6
receptor, one of these residues is a threonine (Thr196), whereas in
most other mammalian 5-HT receptors, the corresponding residue is
alanine. After transient expression in human embryonic kidney 293 cells, we determined the effects of the mutation T196A on
[3H]d-lysergic acid diethylamide (LSD) binding
and adenylyl cyclase stimulation. This mutation produced a receptor
with a 10-fold reduced affinity for [3H]LSD and a 6-fold
reduced affinity for 5-HT. The potency of both LSD and 5-HT for
stimulation of adenylyl cyclase was also reduced by 18- and 7-fold,
respectively. The affinity of other N1-unsubstituted ergolines (e.g.,
ergotamine, lisuride) was reduced 10-30-fold, whereas the affinity of
N1-methylated ergolines (e.g., metergoline, methysergide, mesulergine)
and other ligands, such as methiothepine, clozapine, ritanserin,
amitriptyline, and mianserin, changed very little or increased. This
indicates that in wild-type 5-HT6 receptor, Thr196
interacts with the N1 of N1-unsubstituted ergolines and tryptamines,
probably forming a hydrogen bond. Based on molecular modeling, a serine
residue in transmembrane region IV of the 5-HT2A receptor
has previously been proposed to interact with the N1-position of 5-HT.
When the corresponding residue of the 5-HT6 receptor (Ala154) was converted to serine, no change in the affinity of twelve
5-HT6 receptor ligands or in the potency of 5-HT and LSD could be detected, suggesting that this position does not contribute to
the ligand binding site of the 5-HT6 receptor.
This article has been cited by other articles:
![]() |
R. A. Bakker, D. M. Weiner, T. ter Laak, T. Beuming, O. P. Zuiderveld, M. Edelbroek, U. Hacksell, H. Timmerman, M. R. Brann, and R. Leurs 8R-Lisuride Is a Potent Stereospecific Histamine H1-Receptor Partial Agonist Mol. Pharmacol., March 1, 2004; 65(3): 538 - 549. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Lindner, D. B. Hodges Jr., J. B. Hogan, A. F. Orie, J. A. Corsa, D. M. Barten, C. Polson, B. J. Robertson, V. L. Guss, K. W. Gillman, et al. An Assessment of the Effects of Serotonin 6 (5-HT6) Receptor Antagonists in Rodent Models of Learning J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 682 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Allman, K. M. Page, C. A.M. Curtis, and E. C. Hulme Scanning Mutagenesis Identifies Amino Acid Side Chains in Transmembrane Domain 5 of the M1 Muscarinic Receptor that Participate in Binding the Acetyl Methyl Group of Acetylcholine Mol. Pharmacol., July 1, 2000; 58(1): 175 - 184. [Abstract] [Full Text] |
||||
![]() |
T. Wurch, F. C. Colpaert, and P. J. Pauwels Chimeric Receptor Analysis of the Ketanserin Binding Site in the Human 5-Hydroxytryptamine1D Receptor: Importance of the Second Extracellular Loop and Fifth Transmembrane Domain in Antagonist Binding Mol. Pharmacol., December 1, 1998; 54(6): 1088 - 1096. [Abstract] [Full Text] |
||||